Applied Genetic Technologies Corporation

NasdaqGM:AGTC Voorraadrapport

Marktkapitalisatie: US$12.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Applied Genetic Technologies Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Sue Washer

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris37.4%
Dienstverband CEO20.7yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn1.4yrs
Gemiddelde ambtstermijn bestuur11.3yrs

Recente managementupdates

Recent updates

AGTC receives positive feedback from FDA for manufacturing facility

Jul 26

Applied Genetic Technologies proposes stock offering to fund clinical trials

Jul 12

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

Jan 12

An Assessment Of Applied Genetic Technologies Corporation

Dec 14

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Jul 15

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

May 21
Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

Applied Genetic trades lower after announcing the departure of chief scientific officer

Apr 26

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Feb 05
What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

Jan 06
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Dec 11
What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic

Nov 11

Analyse CEO-vergoeding

Hoe is Sue Washer's beloning veranderd ten opzichte van Applied Genetic Technologies's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2022n/an/a

-US$70m

Jun 30 2022US$1mUS$551k

-US$69m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021n/an/a

-US$63m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021US$1mUS$530k

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020n/an/a

-US$57m

Sep 30 2020n/an/a

-US$50m

Jun 30 2020US$988kUS$530k

-US$46m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019n/an/a

-US$19m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019US$1mUS$514k

-US$2m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

-US$18m

Sep 30 2018n/an/a

-US$19m

Jun 30 2018US$1mUS$502k

-US$21m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017n/an/a

-US$11m

Sep 30 2017n/an/a

-US$4m

Jun 30 2017US$1mUS$487k

US$407k

Mar 31 2017n/an/a

US$6m

Dec 31 2016n/an/a

US$10m

Sep 30 2016n/an/a

US$11m

Jun 30 2016US$2mUS$464k

-US$1m

Compensatie versus markt: Sue's total compensation ($USD1.47M) is above average for companies of similar size in the US market ($USD749.50K).

Compensatie versus inkomsten: Sue's compensation has increased whilst the company is unprofitable.

CEO

Sue Washer (61 yo)

20.7yrs

Tenure

US$1,473,567

Compensatie

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Susan Washer
President20.7yrsUS$1.47m0.21%
$ 26.7k
Jonathan Lieber
Chief Financial Officer1.2yrsUS$1.00mgeen gegevens
Susan Schneider
Chief Medical Officerless than a yearUS$832.63kgeen gegevens
Nicholas Muzyczka
Co-Founder23.8yrsgeen gegevensgeen gegevens
Barry Byrne
Co-Founder23.8yrsgeen gegevensgeen gegevens
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datageen gegevensgeen gegevens
Richard Samulski
Co-Founder23.8yrsgeen gegevensgeen gegevens
Terence Flotte
Co-Founder23.8yrsgeen gegevensgeen gegevens
Gerald Reynolds
Chief Accounting Officer1.4yrsgeen gegevens0.013%
$ 1.6k
Abraham Scaria
Chief Scientific Officerless than a yeargeen gegevensgeen gegevens
Hope D'Oyley-Gay
General Counselless than a yeargeen gegevensgeen gegevens
David Knop
Senior Vice President of Process & Assay Developmentless than a yearUS$141.25kgeen gegevens

1.4yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: AGTC's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Susan Washer
President19yrsUS$1.47m0.21%
$ 26.7k
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datageen gegevensgeen gegevens
Edward Hurwitz
Independent Director10yrsUS$65.23k0.041%
$ 5.1k
Anne VanLent
Independent Director6.3yrsUS$79.23kgeen gegevens
Scott Koenig
Independent Chairman of the Board20.6yrsUS$101.50k0.051%
$ 6.4k
David Birch
Member of Ophthalmology Scientific Advisory Boardno datageen gegevensgeen gegevens
William Aliski
Independent Director4.2yrsUS$78.23k0.013%
$ 1.6k
Peter Campochiaro
Member of Ophthalmology Scientific Advisory Boardno datageen gegevensgeen gegevens
James Rosen
Independent Director12.7yrsUS$72.34k0.0015%
$ 186.7
Paul Kaufman
Member of Ophthalmology Scientific Advisory Boardno datageen gegevensgeen gegevens
Stephen Daiger
Member of Ophthalmology Scientific Advisory Boardno datageen gegevensgeen gegevens
Robert Molday
Member of Ophthalmology Scientific Advisory Boardno datageen gegevensgeen gegevens

11.3yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: AGTC's board of directors are seasoned and experienced ( 11.3 years average tenure).